Key result
LCAT enhances reverse cholesterol transport and favorably modulates atherogenic lipid profiles and atherosclerosis.
Answers are grounded in this paper and cite their sources.
In the past several years significant advances have been made in our understanding of lecithin-cholesterol acyltransferase (LCAT) function. LCAT beneficially alters the plasma concentrations of apolipoprotein B-containing lipoproteins, as well as HDL. In addition, its proposed role in facilitating reverse cholesterol transport and modulating atherosclerosis has been demonstrated in vivo. Analysis of LCAT transgenic animals has established the importance of evaluating HDL function, as well as HDL plasma levels, to predict atherogenic risk.
No takes yet. Share an insight, caveat, or question.
Santamarina-Fojo et al. (2000) conducted a review in Atherosclerosis and lipoprotein metabolism. Lecithin-cholesterol acyltransferase (LCAT) was evaluated. Lecithin-cholesterol acyltransferase (LCAT) beneficially alters plasma apolipoprotein B and HDL concentrations while facilitating reverse cholesterol transport and modulating atherosclerosis in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: